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1. INTRODUCTION {#cam43096-sec-0001}
===============

Extranodal marginal zone B‐cell lymphoma of mucosa associated lymphoid tissue (MALT), also known as MALT lymphoma, comprises 6% to 8% of all non‐Hodgkin lymphomas (NHL).[^1^](#cam43096-bib-0001){ref-type="ref"} MALT lymphomas most commonly affect stomach; however, it has been reported in virtually all tissues.[^2^](#cam43096-bib-0002){ref-type="ref"}, [^3^](#cam43096-bib-0003){ref-type="ref"}, [^4^](#cam43096-bib-0004){ref-type="ref"} MALT lymphoma originating in the lung, also known as pulmonary marginal zone lymphoma (PMZL), is a rare disease representing 9%--14% of MALT lymphomas.[^4^](#cam43096-bib-0004){ref-type="ref"} However, it is the most common NHL affecting the lung. PMZL arises from bronchial associated lymphoid tissue (BALT) which is absent in normal healthy adults. Continuous antigen stimulation as occurs in association with inflammation, smoking, and autoimmune disorders (eg Sjögren\'s syndrome), leads to BALT appearance.[^5^](#cam43096-bib-0005){ref-type="ref"} This chronic antigenic stimulus is considered the underlying cause in PMZL.[^6^](#cam43096-bib-0006){ref-type="ref"} PMZL is associated with smoking in 35%--45% of patients[^6^](#cam43096-bib-0006){ref-type="ref"}, [^7^](#cam43096-bib-0007){ref-type="ref"}, [^8^](#cam43096-bib-0008){ref-type="ref"} and a possible association with *Achromobacter xylosoxidans* infection was described in Europe.[^9^](#cam43096-bib-0009){ref-type="ref"}

Respiratory symptoms are usually present at the time of PMZL diagnosis and diverse patterns of lung abnormalities are observed on imaging studies.[^10^](#cam43096-bib-0010){ref-type="ref"} On computed tomography (CT) scans, PMZL usually manifests with bilateral (60%--70%) and multiple (70%--77%) lesions, without a clear topographic predominance.[^10^](#cam43096-bib-0010){ref-type="ref"} The most frequent patterns are lobar or segmental consolidation followed by nodules and masses.[^6^](#cam43096-bib-0006){ref-type="ref"}, [^10^](#cam43096-bib-0010){ref-type="ref"} The role of ^18^F‐deoxyglucose‐positron emission tomography/CT (FDG‐PET/CT) in MALT lymphoma is not well‐established. Several studies have shown FDG avidity in 80% of PMZL cases with an average SUV~max~ ranging from 3.3 to 7.5. It was suggested that PET/CT may detect previously unrecognized lesions during staging of PMZL.[^10^](#cam43096-bib-0010){ref-type="ref"}, [^11^](#cam43096-bib-0011){ref-type="ref"}

Pulmonary marginal zone lymphoma carries a favorable outcome with a 5‐year overall survival (OS) rates of 90%.[^10^](#cam43096-bib-0010){ref-type="ref"}, [^12^](#cam43096-bib-0012){ref-type="ref"} Presence of mediastinal lymphadenopathy, extrapulmonary MZL, and use of chemotherapy regimens including anthracyclines or cyclophosphamide have been associated with shorter progression‐free survival (PFS) and time to progression.[^6^](#cam43096-bib-0006){ref-type="ref"}, [^10^](#cam43096-bib-0010){ref-type="ref"} The latter may reflect a more advanced disease needing systemic therapeutic approaches. Overall, clinical and radiological variables associated with worse outcome remain poorly understood.

Herein we report a single‐institution experience with a large cohort of patients with PMZL focusing on clinical features, radiological presentation, therapeutic approaches, and outcomes.

2. MATERIALS AND METHODS {#cam43096-sec-0002}
========================

All patients presenting with MALT lymphoma involving the lung and/or pleura diagnosed and treated at our institution between January 1995 and September 2019 were included in this analysis. Twenty‐seven patients presented with respiratory presentation and during staging were found to have extranodal MZL limited to the lungs. Additional 13 patients presented with respiratory complains with or without additional complains related to other organs and were found to have concomitant pulmonary and extrapulmonary extranodal MZL during staging. Patients with higher grade transformation (HGT) at presentation were excluded (n = 2) from this analysis. The patients were identified by a review of the Florida Cancer Registry database. The institutional review board approved this study, which followed the tenets of the Declaration of Helsinki. All specimens were reviewed by expert hematopathologists and MZL diagnosis was confirmed using the morphologic and immunophenotypic features defined by the WHO classification.[^13^](#cam43096-bib-0013){ref-type="ref"} Concomitant amyloid was detected at diagnosis in one patient only. Medical records were reviewed to obtain information on patients' demographics, laboratory findings, smoking, staging, treatments, dates of diagnosis, relapse, transformation, and last follow‐up or death.

Staging evaluation was not standardized during the study interval, but included a complete physical examination; hematological and chemical survey with LDH; chest X‐rays and computerized tomography (CT) of the chest, abdomen, and pelvis in all the patients. PET‐CT, endoscopies, orbital or other magnetic resonance imaging (MRI), and ultrasound of thyroid or salivary glands were performed if clinically indicated. The decision to perform a staging bone marrow (BM) biopsy was left to the discretion of the treating oncologist. Based on the Ann Arbor staging classification,[^14^](#cam43096-bib-0014){ref-type="ref"} bilateral lung involvement was classified as stage IV. All the available chest X‐rays, CT scans, and FDG‐PET/CT scans were reviewed and revised by a board‐certified radiologist and nuclear medicine physician (RK).

2.1. Statistical analyses {#cam43096-sec-0003}
-------------------------

Distributions of demographic and clinical characteristics were listed as frequency and percent. Missing values, except for BM involvement and presence of monoclonal gammopathy (MG), were grouped with the "low‐risk category" because after reviewing the clinical information they were felt more likely to be a negative/normal result. The MALT‐lymphoma International Prognostic Index (MALT‐IPI) was calculated as reported.[^15^](#cam43096-bib-0015){ref-type="ref"}

Progression‐free survival was defined as the time from diagnosis to transformation after diagnosis, progression/relapse, or death, whichever occurred first. OS was defined as the time from diagnosis to death. Event‐free patients were censored at the date of last follow‐up. PFS and OS curves were estimated using the Kaplan‐Meier method and compared using the log‐rank test. Univariable and multivariable analyses using Cox proportional hazards regression were conducted to evaluate the effect of potential prognostic variables on PFS and OS. Multivariable models were derived using stepwise selection among candidate variables with cut‐offs *P* ≤ 50% to enter and *P* ≤ 5% to stay in the model. We first derived model 1 testing variables, except the MALT‐IPI. Next, we derived model 2, by forcing MALT‐IPI and testing other variables that were not part of that index.

3. RESULTS {#cam43096-sec-0004}
==========

3.1. Clinical characteristics of PMZL patients {#cam43096-sec-0005}
----------------------------------------------

Total of 40 patients with PMZL were diagnosed and treated at our institution between January 1995 and September 2019. Additional two patients with concomitant diagnosis of HGT were excluded from this analysis. Clinical characteristic of the 40 patients with PMZL are presented in Table [1](#cam43096-tbl-0001){ref-type="table"}. PMZL was diagnosed in 22 men (55%) and 18 women (45%) with a median age of 58.5 years (range 17.0‐80.0). At the time of diagnosis 67.5% had advanced disease (stage III‐IV), 22.5% presented with B symptoms, elevated LDH was detected in 32.5% of the patients and 37.5% presented with a MALT‐IPI score of 2. Staging BM biopsy was negative in 55% (22/30) of the patients with missing data in 10 patients. Five (12.5%) patients had an associated autoimmune disease but none had a history of Sjögren\'s syndrome. MG was present in 3 (7.5%) patients (IgM lambda, free light chain lambda, IgA kappa, and IgG lambda). Twelve patients (30%) had a history of smoking but data were missing for six (14%). No HGT was observed during the study follow‐up period.

###### 

Characteristics of the study population

  Variable                           N    \%
  ---------------------------------- ---- -------
  Total                              40   100.0
  Age                                     
  \<70                               30   75.0
  ≥70                                10   25.0
  Gender                                  
  Male                               22   55.0
  Female                             18   45.0
  Race                                    
  White                              15   37.5
  Hispanic                           18   45.0
  Black                              5    12.5
  Other/Unknown                      2    5.0
  Tumor stage                             
  Stage I‐II                         13   32.5
  Stage III‐IV                       27   67.5
  LDH                                     
  Normal LDH                         27   67.5
  Elevated LDH                       13   32.5
  Anemia (Hg \< 12 g/dL)                  
  No                                 29   72.5
  Yes                                8    20.0
  Unknown                            3    7.5
  Bone marrow involvement                 
  Negative                           22   55.0
  Positive                           8    20.0
  Unknown                            10   25.0
  Autoimmune disease                      
  No                                 35   87.5
  Yes                                5    12.5
  Monoclonal gammopathy                   
  No                                 28   70.0
  Yes                                3    7.5
  Unknown                            9    22.5
  B symptoms                              
  No B symptoms                      31   77.5
  B symptoms                         9    22.5
  PET/CT 5PS                              
  No PET/CT                          25   62.5
  DS 1‐3                             1    2.5
  DS 4‐5                             14   35.0
  Smoking status                          
  Non‐smoking                        22   55.0
  Smoking                            12   30.0
  Unknown                            6    15.0
  Organ involvement                       
  Extrapulmonary MZL                 13   32.5
  PMZL                               27   67.5
  Mediastinal lymphadenopathy (ML)        
  Not present                        16   40.0
  Present                            18   45.0
  Unknown                            6    15.0
  Pleural effusion (PE)                   
  Not present                        27   67.5
  present                            7    17.5
  Unknown                            6    15.0
  Cavitation                              
  Not present                        31   77.5
  Present                            3    7.5
  Unknown                            6    15.0
  Mass                                    
  Not present                        19   47.5
  Present                            15   37.5
  Unknown                            6    15.0
  Size                                    
  \<2 cm                             4    10.0
  2‐5 cm                             18   45.0
  \>5 cm                             9    22.5
  0/Unknown                          9    22.5
  Unifocal/Multifocal                     
  Unifocal                           12   30.0
  Multifocal                         22   55.0
  Unknown                            6    15.0
  MALT‐IPI score                          
  0                                  9    22.5
  1                                  14   35.0
  2                                  15   37.5
  3                                  2    5.0

Abbreviations: 5PS, five‐point scale; DS, Deauville score; Hg, hemoglobin; LDH: lactate dehydrogenase; MALT‐IPI, mucosa‐associated lymphoid tissue lymphoma international prognostic index; MZL, marginal zone lymphoma; PET/CT, positron emission tomography; PMZL, pulmonary marginal zone lymphoma.
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3.2. Pulmonary radiological characteristics of PMZL patients {#cam43096-sec-0006}
------------------------------------------------------------

The involvement was unilateral in 29 (72%) and bilateral in 11 (28%) patients. Lung involvement was multifocal in 22 (55%) of patients. Twenty‐seven patients had lung only PMZL while 13 patients had extrapulmonary MZL with lung involvement. From 27 patients with only lung involvement, nine (33.3%) had stage IV due to multiple lung lesions, five (18.5%) due to BM involvement, while 13 (48.2%) had stage I disease.

Radiological scans were available and were reviewed for 34 patients and shown in Table [1](#cam43096-tbl-0001){ref-type="table"} and Figure [1](#cam43096-fig-0001){ref-type="fig"}. Consolidation or air‐bronchogram pattern were the most common presenting findings seen on CT scans in 22 (65%) of patients, followed by lung nodules in 18 (53%) patients. Ground glass opacities (GGO) were seen in 14 (41%), while pleural effusion was observed in seven (21%) patients. Mass like lesion was detected in 15 (44%) patients, cavitary lesions in three (9%), and lymphangitic spread was seen on chest CT in three (9%) patients. We measured lesion size and classified patients based on the size of their largest lesion into three categories: \<2 cm in 4 (12%) patients, 2‐5 cm in 18 (53%) and more than 5 cm in nine (27%), while lesion size data were unavailable for three (9%) patients.

![Radiological manifestations of pulmonary marginal zone lymphoma. A and B, focal ground glass opacity with air bronchograms and mild FDG‐uptake in the left upper lobe; (C and D), nodular lesion with intense FDG‐uptake in the left lower lobe; (E and F), pulmonary mass with intense FDG‐uptake in the right upper lobe; (G and H), multifocal bilateral lung parenchymal opacities with small left pleural effusion; (I and J), nodular interstitial thickening indicating lymphangitic spread of lymphoma, also noted to have mediastinal and hilar adenopathy on CT with contrast; (K), focal area of consolidation with homogeneous enhancement in the right middle lobe on CT with contrast; (L), cavitary consolidation in the left lower lobe with an additional cavitary nodule in the right middle lobe](CAM4-9-5051-g001){#cam43096-fig-0001}

FDG‐PET/CT scan data were available in 15 patients, with 14 (93.3%) patients having FDG‐avid disease, as demonstrated by presence of hypermetabolic lesions corresponding to the areas of PMZL. Fourteen patients demonstrated a Deauville score of 4‐5, one patient demonstrated a Deauville score of 1 (Table [1](#cam43096-tbl-0001){ref-type="table"}). The patient with low FDG‐avidity presented with ground‐glass opacities, air‐bronchogram, and nodular lesions of 2‐5 cm on CT scans. SUV max in FDG avid cases ranged from 2.5 to 9.1 with a median SUV max of 4.0. No patient was upstaged based on the PET/CT scan.

3.3. Treatment {#cam43096-sec-0007}
--------------

Initial treatment at the time of PMZL diagnosis in our cohort of 40 patients consisted of immunotherapy, chemotherapy or both in 26 (65%) patients, radiation therapy only in three (7.5%) patients, combined modality therapy (radiation and immuno/chemotherapy or immuno/chemotherapy and surgery) in five (12.5%) patients, and surgical resection in four (10%) patients (Table [2](#cam43096-tbl-0002){ref-type="table"}). Two (5%) of the 40 patients were never treated and remained on active surveillance. The overall response rate in 38 treated patients was 86.9% (25 CR and 8 PR). Overall response per treatment modality was 80.7% (CR 15 and PR 6) for immuno/chemotherapy only, 100% (CR 3) for radiation therapy only, 100% (CR 3 and PR 2) for combined modality, and 100% (CR 4) for surgical resection. It is important to note that all the patients treated with surgical resection, radiation therapy, or combined modality therapy had localized disease only.

###### 

Treatments and response

  Variable                                          N    \%
  ------------------------------------------------- ---- -------
  Total                                             40   100.0
  Treatment                                              
  Active surveillance                               2    5.0
  Surgery only                                      4    10.0
  RT only                                           3    7.5
  Chemo only                                        26   65.0
  Chemo + surgery                                   1    2.5
  Chemo + RT                                        4    10.0
  Chemotherapy regimens                             31   100
  Rituximab                                         10   32.2
  R‐CVP                                             6    19.3
  R‐CHOP                                            5    16.1
  Ibritumomab Tiuxetan/rituximab                    5    16.1
  Bendamustine/Rituximab                            2    6.4
  Rituximab/Lenalidomide                            1    3.3
  Rituximab/Chlorambucil                            1    3.3
  Other[^a^](#cam43096-note-0004){ref-type="fn"}    1    3.3
  Clinical response (n = 38 excluded 2 untreated)        
  CR                                                25   65.8
  PR                                                8    21.1
  SD                                                1    2.6
  PD                                                4    10.5

Abbreviations: CR, complete response; PD, progression of disease; PR, partial response; R‐CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R‐CVP, rituximab, cyclophosphamide, vincristine and prednisone; RT, radiation therapy; SD, stable disease.

Rituximab/Methotrexate/Procarbazine.
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3.4. Progression‐free survival and overall survival {#cam43096-sec-0008}
---------------------------------------------------

With a median follow‐up of 8.4 years (range 0.07‐18.44), 22 PFS events (17 relapses and 5 deaths) were seen among the 38 treated patients. All the PFS events were seen among the 33 patients treated with immuno/chemotherapy or combined modality therapy while there were no PFS events in patients treated with surgery or radiation therapy alone. Table [3](#cam43096-tbl-0003){ref-type="table"} summarizes therapies given to patients upon relapse and patients' outcome. The seven patients treated with either surgery (n = 4) or radiation therapy (n = 3), as primary modalities, remained alive and free of disease. Two patients on observation also remained alive and stable, not requiring any further therapy after 8.4 and 8.6 years of follow‐up respectively.

###### 

Detailed characteristics of 17 relapsed PMZL patients

  Patient   Site of disease                       Initial treatment                      Response 1   Site of relapse                                        Treatment                             Response 2   Status     Cause of death
  --------- ------------------------------------- -------------------------------------- ------------ ------------------------------------------------------ ------------------------------------- ------------ ---------- ----------------------
  1         Lung, pleural effusion                Rituximab                              CR           Lung, Bone, BM                                         R‐CVP                                 CR           Alive      NA
  2         Lung, pleural effusion                Rituximab                              CR           Lacrimal gland, lung, LNs                              BR                                    SD           Alive      NA
  3         Lung, gastric, skin                   Ibritumomab Tiuxetan/rituximab         CR           Skin, subcutaneous soft tissue with skin amyloidosis   R‐CVP                                 SD           Deceased   Unknown
  4         Lung, LNs, adrenal, Horner syndrome   Rituximab                              PD           Lung, LNs, adrenal, Horner syndrome                    R‐CHOP, HDMTX                         CR           Alive      NA
  5         Lung                                  R‐CHOP                                 CR           Lung, LNs                                              BR                                    CR           Alive      NA
  6         Pleural effusion, LNs                 Rituximab                              PD           Pleural effusion                                       BR                                    PR           Alive      NA
  7         Lung, spinal cord, Bone, +CSF         Rituximab, procarbazine, IT‐MTX‐AraC   PD           New brain lesion                                       DHAP, HDMTX and IT‐MTX, AraC          CR           Alive      NA
  8         Lung, spleen, bone                    Ibritumomab Tiuxetan/rituximab         PR           Lung                                                   RCVP                                  PR           Alive      NA
  9         Lung                                  Rituximab                              CR           Lung                                                   BR, RT                                CR           Deceased   Unknown
  10        Lung and BM                           Rituximab + Surgery                    CR           Parotid                                                Rituximab, RT                         CR           Deceased   Unknown
  11        Lung and BM                           Rituximab                              CR           Lung                                                   BR                                    CR           Deceased   Unknown
  12        Lung, pelvic mass                     Rituximab                              CR           Lung, Gastric, perineal                                Rituximab                             PR           Alive      NA
  13        Lung, Renal, LNs                      R‐CVP                                  PR           Lung, Renal                                            Ibritumomab Tiuxetan/rituximab        PR           Alive      NA
  14        Lung, LNs                             R‐CVP                                  CR           Lung                                                   R‐CHOP                                PR           Alive      NA
  15        Lung, gastric, BM                     R‐CVP                                  PD           Gastric and lung                                       Surveillance                          SD           Deceased   SCC of head and neck
  16        Lung                                  R‐CHOP                                 PR           Lung                                                   Rituximab Chlorambucil, Gamma knife   CR           Alive      NA
  17        Lung, LNs                             BR                                     CR           LNs                                                    Surveillance                          SD           Alive      NA

Boldface indicates significance at P \< .05. Abbreviations: BM, Bone marrow; BR, bendamustine, rituximab; CR, complete response; DHAP, dexamethasone, cytarabine, cisplatin; HDMTX, high dose methotrexate; IT MTX, intrathecal methotrexate; LNs, lymph nodes; NA, not applicable; PD, disease progression; PMZL, pulmonary marginal zone lymphoma; PR, partial response; R‐CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R‐CVP, rituximab, cyclophosphamide, vincristine, prednisone; SCC, squamous cell carcinoma; SD, stable disease.
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There were 10 deaths during the follow‐up period, including two attributed to PMZL (n = 1) or PMZL treatment (n = 1). A patient with the shortest follow‐up of 1.5 months died of PMZL. Four patients died secondary to other causes: squamous cell carcinoma of head and neck (n = 1), peripheral T cell lymphoma that developed after renal transplant (n = 1), autoimmune hemolytic anemia (n = 1), and stab wound to the chest (n = 1). The cause of death was unknown in four patients who died in CR (n = 3) or with SD (n = 1) at the time of last follow‐up.

In treated patients, the median PFS was 7.5 years (95% CI 1.8‐9.5) and the median OS was 15.7 years (95% CI 9.3‐NE; Figure [2A](#cam43096-fig-0002){ref-type="fig"}). The 10‐year PFS and OS were 32.9% (95% CI 16.4%‐50.5%) and 70.2% (95% CI 49.9%‐83.6%) respectively.

![Kaplan‐Meier curves for progression free survival (PFS) and overall survival (OS) in 40 treated patients with pulmonary marginal zone lymphoma based on clinical features present at diagnosis. A, in all the patients; (B), by lactate dehydrogenase (LDH); (C), by B symptoms; (D), by stage (I‐II vs III‐IV); (E), by complete response (CR) after initial therapy; (F), by presence of extrapulmonary (Extrapulm) marginal zone lymphoma (MZL)](CAM4-9-5051-g002){#cam43096-fig-0002}

In the nine patients who initially were treated with rituximab alone, the mPFS was 7.5 (1.3‐9.1) years and in patients achieving CR, the median duration of response was 5.2 years (range 0.6‐9.5).

We then analyzed prognostic factors associated with PFS and OS (Table [4](#cam43096-tbl-0004){ref-type="table"}). PFS was significantly shorter in patients with elevated LDH at presentation (Figure [2B](#cam43096-fig-0002){ref-type="fig"}), presence of B symptoms (Figure [2C](#cam43096-fig-0002){ref-type="fig"}), advanced stage (Figure [2D](#cam43096-fig-0002){ref-type="fig"}), failure to achieve CR after initial treatment (Figure [2E](#cam43096-fig-0002){ref-type="fig"}), and presence of extrapulmonary MZL (Figure [2F](#cam43096-fig-0002){ref-type="fig"}). Nevertheless, none of these variables affected the OS (Figure [2B‐F](#cam43096-fig-0002){ref-type="fig"}). Univariable analyzes (Table [4](#cam43096-tbl-0004){ref-type="table"}) showed association between shorter PFS and elevated LDH at presentation (HR = 2.57, 95% CI 1.16‐6.51, *P* = .022), advanced stage (HR = 9.84, 95% CI of 2.24‐43.3, *P* = .002), and failure to achieve CR after initial treatment (HR = 3.95, 95% CI 1.64‐9.52, *P* = .002). Patients without extrapulmonary MZL had longer PFS (HR = 3.41, 95% CI 1.35‐8.60, *P = *.009). However, none of these variables were associated with shorter OS (Table [4](#cam43096-tbl-0004){ref-type="table"}).

###### 

Univaria Cox models for progression‐free survival (PFS) and overall survival (OS) in 38 treated patients

  Variable                           N    PFS (21 events)   OS (10 events)                                           
  ---------------------------------- ---- ----------------- --------------------- ---------- --- ------------------- ------
  Gender                                                                                                             
  Male                               20   13                Reference                        5   Reference           
  Female                             18   8                 0.63 (0.26, 1.51)     .299       5   1.11 (0.32, 3.88)   .872
  Race                                                                                                               
  White                              14   9                 Reference                        4   Reference           
  Hispanic                           17   7                 0.75 (0.28, 2.04)     .574       4   1.30 (0.32, 5.31)   .711
  Black                              5    5                 2.58 (0.85, 7.82)     .095       2   1.69 (0.30, 9.51)   .553
  Other/Unknown                      2    ‐                 NE                               ‐   NE                  
  Age                                                                                                                
  \<70                               30   15                Reference                        6   Reference           
  ≥70                                8    6                 2.11 (0.81, 5.48)     .126       4   2.59 (0.72, 9.28)   .144
  Tumor stage                                                                                                        
  Stage I‐II                         12   2                 Reference                        1   Reference           
  Stage III‐IV                       26   19                9.84 (2.24, 43.3)     **.002**   9   4.98 (0.63, 39.3)   .128
  LDH                                                                                                                
  Normal LDH                         25   11                Reference                        5   Reference           
  Elevated LDH                       13   10                2.75 (1.16, 6.51)     **.022**   5   1.85 (0.52, 6.58)   .339
  MALT‐IPI                                                                                                           
  0‐1                                22   8                 Reference                        4   Reference           
  2‐3                                16   13                3.98 (1.63, 9.73)     **.002**   6   2.02 (0.56, 7.27)   .280
  B symptoms                                                                                                         
  Non‐B symptoms                     29   13                Reference                        5   Reference           
  B symptoms                         9    8                 2.41 (0.99, 5.84)     .052       5   3.02 (0.87, 10.5)   .083
  Smoking status                                                                                                     
  Non‐smoking                        21   14                Reference                        8   Reference           
  Smoking                            11   4                 0.46 (0.15, 1.41)     .175       ‐   NE                  
  Unknown                            6    3                 0.51 (0.14, 1.78)     .288       2   0.81 (0.17, 3.90)   .791
  Lung disease                                                                                                       
  Pulm MZL                           26   12                Reference                        3   Reference           
  Pulm/Extrapulm--MZL                12   9                 3.41 (1.35, 8.60)     **.009**   7   1.02 (0.26, 3.97)   .973
  Mediastinal lymphadenopathy (ML)                                                                                   
  Non‐ML                             14   5                 Reference                        2   Reference           
  ML                                 18   12                2.72 (0.94, 7.86)     .065       6   3.28 (0.64, 16.9)   .155
  Unknown                            6    4                 1.41 (0.38, 5.27)     .610       2   1.27 (0.17, 9.67)   .815
  Clinical response                                                                                                  
  CR                                 25   11                Reference                        5   Reference           
  Non‐CR                             13   10                3.95 (1.64, 9.52)     **.002**   5   2.97 (0.80, 11.1)   .105
  Pleural effusion (PE)                                                                                              
  Non‐PE                             25   12                Reference                        6   Reference           
  PE                                 7    5                 2.28 (0.80, 6.49)     .124       2   1.52 (0.30, 7.65)   .608
  Unknown                            6    4                 0.94 (0.30, 2.93)     .916       2   0.72 (0.13, 3.89)   .707
  Cavitation                                                                                                         
  Non‐Cavitation                     29   15                Reference                        7   Reference           
  Cavitation                         3    2                 49.2 (4.18, 579.00)   **.002**   1   2.20 (0.27, 18.1)   .462
  Unknown                            6    4                 0.86 (0.28, 2.60)     .787       2   0.71 (0.14, 3.75)   .690
  Mass                                                                                                               
  Non‐Mass                           18   9                 Reference                        7   Reference           
  Mass                               14   8                 1.07 (0.41, 2.79)     .883       1   0.16 (0.02, 1.31)   .088
  Unknown                            6    4                 0.81 (0.25, 2.66)     .734       2   0.43 (0.08, 2.14)   .300
  Tumor size (cm)                                                                                                    
  \<2 cm                             4    2                 Reference                        1   Reference           
  2‐5 cm                             16   7                 0.83 (0.17, 4.00)     .813       4   1.45 (0.13, 16.6)   .767
  \>5 cm                             9    7                 1.94 (0.40, 9.37)     .411       3   2.20 (0.18, 26.9)   .537
  0/Unknown                          9    5                 0.61 (0.12, 3.16)     .555       2   0.64 (0.06, 7.32)   .719
  Unifocal/Multifocal                                                                                                
  Unifocal                           11   2                 Reference                        ‐   Reference           
  Multifocal                         21   15                7.61 (1.72, 33.7)     **.007**   8   NE                  
  Unknown                            6    4                 3.30 (0.60, 18.1)     .168       2   NE                  

Boldface indicates significance at *P* \< .05. Abbreviations: MZL, marginal zone lymphoma; NE, not estimable; Pulm, pulmonary; extrapulm; extrapulmonary.
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A multivariable analysis (Table [5](#cam43096-tbl-0005){ref-type="table"}) demonstrated that age ≥70 (HR = 3.22, 95% CI 1.04‐9.95, *P* = .042), elevated LDH (HR = 3.55, 95% CI 1.38‐9.14, *P* = .009), advanced stage (HR = 6.76, 95% CI 1.48‐31.0, *P* = .014), not achieving CR (HR = 7.18, 95% CI 2.25‐22.9, *P* = .001), and MALT‐IPI of 2‐3 (HR of 7.24, 95% CI 2.55‐20.53, *P* = .001) were associated with shorter PFS. However, none of these variables were associated with shorter OS.

###### 

Multivariable Cox models for progression‐free survival (PFS) and overall survival (OS) in 38 treated patients

  Variable             Category             PFS (21 events)   OS, event (10 events)               
  -------------------- -------------------- ----------------- ----------------------- ----------- --
  Model 1                                                                                         
  Age                  \<70                 Reference                                 Reference   
  ≥70                  3.22 (1.04, 9.95)    **.042**          3.25 (0.76, 13.9)       .111        
  Tumor stage          Stage I‐II           Reference                                 Reference   
  Stage III‐IV         6.76 (1.48, 31.0)    **.014**          2.42 (0.27, 21.7)       .429        
  LDH                  Normal LDH           Reference                                 Reference   
  Elevated LDH         3.55 (1.38, 9.14)    **.009**          1.68 (0.44, 6.40)       .450        
  Clinical response    CR                   Reference                                 Reference   
  Non‐CR               7.18 (2.25, 22.9)    **\<.001**        3.39 (0.76, 15.2)       .110        
  Model 2                                                                                         
  MALT‐IPI             0‐1                  Reference                                 Reference   
  2‐3                  7.24 (2.55, 20.53)   **\<.001**        2.09 (0.58, 7.54)       .260        
  Lung disease         Pulm‐MZL             Reference                                 Reference   
  Extrapulm/Pulm‐MZL   2.49 (0.99, 6.25)    .052              0.84 (0.21, 3.30)       .803        
  Clinical response    CR                   Reference                                 Reference   
  Non‐CR               7.33 (2.58, 20.85)   **\<.001**        3.03 (0.81, 11.32)      .099        

Boldface indicates significance at *P* \< .05. Abbreviations: CR, complete response; LDH, lactate dehydrogenase; MALT‐IPI, mucosa‐associated lymphoid tissue lymphoma international prognostic index; MZL, marginal zone lymphoma; Pulm, pulmonary; extrapulm; extrapulmonary.
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There were no differences in PFS and OS by lesion size (Figure [3A](#cam43096-fig-0003){ref-type="fig"}). Patients with multifocal disease on CT chest tended to have shorter PFS as compared to patients with unifocal disease (HR = 7.61, 95% CI of 1.72‐33.7, *P* = .007; Figure [3B](#cam43096-fig-0003){ref-type="fig"}), as also did patients with cavitary lesions (HR = 49.2, 95% CI 4.18‐579.00, *P* = .002; Figure [3C](#cam43096-fig-0003){ref-type="fig"}). However, radiologic findings were not associated with statistically significant shorter OS. (Figure [3A,C](#cam43096-fig-0003){ref-type="fig"}).

![Kaplan‐Meier curves for progression free survival (PFS) and overall survival (OS) in 34 treated patients with pulmonary marginal zone lymphoma based on radiological findings at diagnosis. A, by size of lesion (\<2 cm vs 2‐5 cm vs \>5 cm); (B), by site of disease (unifocal vs multifocal disease); (C), by presence of cavitation](CAM4-9-5051-g003){#cam43096-fig-0003}

4. DISCUSSION {#cam43096-sec-0009}
=============

Pulmonary marginal zone lymphoma is a rare lymphoma, usually seen in patients older than 60 years old and characterized by an indolent course.[^8^](#cam43096-bib-0008){ref-type="ref"} The present study aimed to identify clinical and radiological findings associated with shorter survival in a large cohort of patients from a single institution followed for more than 8 years. The overall outcome was excellent with only 10 deaths, most of which were non‐PMZL related.

In line with prior studies, most patients included in our cohort presented with normal LDH (66.7%), absence of B symptoms (78.6%), and negative staging BM biopsy (57.1%); however, advanced stage (66.7%) at diagnosis was more frequent in our cohort compared to prior studies.[^8^](#cam43096-bib-0008){ref-type="ref"}, [^10^](#cam43096-bib-0010){ref-type="ref"} Radiologically, consolidation and nodule(s) followed by pulmonary mass were the most common radiological findings, as previously reported[^6^](#cam43096-bib-0006){ref-type="ref"}, [^10^](#cam43096-bib-0010){ref-type="ref"}; however, we also observed lymphangitic spread and cavitations that are not commonly reported.[^5^](#cam43096-bib-0005){ref-type="ref"}, [^8^](#cam43096-bib-0008){ref-type="ref"}, [^10^](#cam43096-bib-0010){ref-type="ref"}

Clinical factors associated with shorter survival in PMZL are still largely unknown and controversial. Oh et al reported shorter median time to progression and 5‐year OS in PMZL patients presenting with extrapulmonary (1.1 vs 6.2 years; *P* = .030 and 65.5% vs 95.95; *P* = .016, respectively) and lymph node involvement (2.4 vs 5.6 years, *P* = .024 and 80.7% vs 94.7%; *P* = .025 respectively).[^6^](#cam43096-bib-0006){ref-type="ref"} However, extrapulmonary MZL was not associated with inferior prognosis in another study.[^10^](#cam43096-bib-0010){ref-type="ref"} In our study, extrapulmonary MZL was associated with shorter PFS. Additional clinical factors associated with shorter PFS in the current study were advanced stage, elevated LDH, failure to achieved CR after frontline therapy, presence of cavitary lesions, and multifocal disease. In multivariable analysis, MALT‐IPI\>1 and independent variables comprising this prognostic score as well as inability to achieve CR after frontline treatment were associated with shorter PFS. However, we did not identify any clinical or radiological finding associated with shorter OS likely due to the fact that majority of causes of death in our patients were unrelated to lymphoma with only two patients succumbing to lymphoma. These findings indicate excellent prognosis PMZL patients with lymphoma‐related OS of 94.9% (95% CI 81.25%‐98.7%) at 5, 10, and 15 years respectively.

Recent studies have demonstrated the utility of FDG‐PET/CT in small cohorts of PMZL with FDG‐avidity in 80%‐100% of patients.[^11^](#cam43096-bib-0011){ref-type="ref"} Our study supports prior observations demonstrating FDG‐avidity in PMZL with most patients presenting FDG‐uptake above liver background. Only one patient had disease detected on PET/CT that was not previously seen on CT scans, but not leading to upstaging. Furthermore, PET/CT was not diagnostic for BM involvement in our patients, however, the number of analyzed cases is small.

Higher grade transformation, reported in 3.8%‐8% of patients with MZL,[^16^](#cam43096-bib-0016){ref-type="ref"}, [^17^](#cam43096-bib-0017){ref-type="ref"}, [^18^](#cam43096-bib-0018){ref-type="ref"} is typically associated with shorter survival---a 5‐year OS of 65% after HGT.[^17^](#cam43096-bib-0017){ref-type="ref"} The incidence of HGT in PMZL patients is largely unknown. In a large study (n = 467) evaluating clinicopathological features of HGT in MALT lymphoma, none of the patients with PMZL transformed to DLBCL.[^18^](#cam43096-bib-0018){ref-type="ref"} Similarly, none of our patients experienced HGT during follow‐up. This finding in combination with low lymphoma‐associated mortality may suggest a different biology and natural history of PMZL in comparison to MALT lymphoma originating in other locations.

Currently, there is no standard/uniform treatment approach for PMZL patients. This is due to absence of large studies and randomized clinical trials, as well as favorable outcomes with multiple therapeutic modalities.[^8^](#cam43096-bib-0008){ref-type="ref"} Accepted treatment options include observation, radiation, surgical resection, and immunochemotherapy. Leyfman et al reported a 6‐year event‐free survival (EFS) and OS of 63% (95% CI 50%‐80%) and 88% (95% CI 77%‐100%), respectively, in patients managed with active surveillance.[^19^](#cam43096-bib-0019){ref-type="ref"} Nevertheless, complete surgical resection have resulted in excellent long‐term disease free survival and may be curative in localized PMZL patients.[^20^](#cam43096-bib-0020){ref-type="ref"}, [^21^](#cam43096-bib-0021){ref-type="ref"} Our findings support these prior observations, as all our patients treated with surgery achieved CR and remained without evidence of disease relapse after a prolonged follow‐up. Similarly, patients treated with radiation therapy (median dose 34 Gy, range 30‐36) achieved excellent outcomes providing further evidence that these two modalities may be preferentially considered for treatment of patients with localized PMZL.

Immunochemotherapy is usually reserved for symptomatic patients with extensive disease. Okamura et al evaluated the activity of a single agent rituximab in PMZL (n = 8) that resulted in an ORR of 75% (CR 62.5% and PR 12.5%) and mPFS of 5.5 years (range 0.8‐7.26 years).[^22^](#cam43096-bib-0022){ref-type="ref"} In our patients treated with rituximab as a single agent, the ORR was 89% and mPFS was 7.5 years (range 1.3‐9.1 years), representing an excellent option in patients requiring systemic therapy.

In summary, our findings confirm excellent outcomes and possible cure in patients with localized PMZL treated with surgery or radiation therapy. Several clinical and radiological features associated with shorter PFS were identified. However, no clinical characteristics associated with shorter OS were detected, likely due to the indolent nature and low PMZL‐related mortality in these patients. Multicenter collaborative studies are needed to define the best therapeutic approach in PMZL patients.
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